PropertyValue
?:abstract
  • Allergic diseases affect one third of general population and usually require regular application of anti-allergic treatment of allergen immuno-therapy Allergic people and patients with chronic allergic respiratory diseases, based on the published studies and case report series, do not yield an increased risk for obtaining COVID-19 compared to the general population Anti-allergic medicaments /with the exception of systemic corticosteroids) do not represent a risk in relation with COVID-19 and its complicated course Patients should continue in their chronic anti-allergic treatment (including biologicals, immunosuppressants, and corticosteroids) without the withdrawal or tapering the dose Patients should continue also in the applied allergen immunotherapy In case of acquiring COVID-19, it is necessary to contact the caring specialists with the highly-individualized re-assessment of the therapeutic strategy The aim is to maintain the achieved control over allergic disease
is ?:annotates of
?:creator
?:journal
  • Alergie
?:license
  • unk
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:source
  • WHO
?:title
  • Allergic diseases in the era of covid-19 pandemic
?:type
?:who_covidence_id
  • #844430
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/mdrozdnv>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/mdrozdnv>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all